New hope for stomach cancer: experimental combo enters final trial phase
NCT ID NCT07118527
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a new combination of drugs (SHR-A1811, adebrelimab, and chemotherapy) works better than the current standard treatment for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The study will enroll about 600 participants and measure how long they live without their cancer getting worse, as well as overall survival. The goal is to find a more effective first-line therapy for this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A1811 (a targeted drug) combined with adebrelimab (immunotherapy) and chemotherapy (capecitabine or fluorouracil)
What this could lead to
If successful, this could offer a new first-line treatment option for advanced stomach cancer, potentially improving how long patients live without their cancer growing.
What could go wrong
This is an early-stage phase 3 trial, so results are not yet known. The new combination may not be more effective than current standard therapy and could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
Contact
-
Zhongshan Hospital，Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact